AR103508A2 - PROCESO PARA LA PREPARACIÓN DE OXI-(1H)-QUINOLIN-2-ONAS 5-(a-HALOACETILO)-8-SUSTITUIDAS - Google Patents
PROCESO PARA LA PREPARACIÓN DE OXI-(1H)-QUINOLIN-2-ONAS 5-(a-HALOACETILO)-8-SUSTITUIDASInfo
- Publication number
- AR103508A2 AR103508A2 ARP160100188A ARP160100188A AR103508A2 AR 103508 A2 AR103508 A2 AR 103508A2 AR P160100188 A ARP160100188 A AR P160100188A AR P160100188 A ARP160100188 A AR P160100188A AR 103508 A2 AR103508 A2 AR 103508A2
- Authority
- AR
- Argentina
- Prior art keywords
- quinolin
- hydroxy
- acetyl
- oxy
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
La presente solicitud se refiere un procedimiento para preparar oxi-(1H)-quinolin-2-onas 5-(a-haloacetil)-8-substituidas. El procedimiento involucra, (i) hacer reaccionar, (a) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación y un ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; o (b) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación para formar 8-acetoxi-(1H)-quinolin-2-ona, y tratar, in situ, la 8-acetoxi-(1H)-quinolin-2-ona con un ácido Lewis para formar la 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; o (c) 8-acetoxi-(1H)-quinolin-2-ona con ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; (ii) hacer reaccionar la 5-acetil-8-hidroxi-(1H)-quinolin-2-ona preparada en el paso (i) con un compuesto que tiene la fórmula RL en presencia de una base y un solvente para formar oxi-(1H)-quinolin-2-ona 5-acetil-8-substituida, en donde R es un grupo protector y L es un grupo saliente; y (iii) hacer reaccionar la oxi-(1H)-quinolin-2-ona 5-acetil-8-substituida con un agente de halogenación en presencia de un solvente para formar oxi-(1H)-quinolin-2-ona 5-(a-haloacetil)-8-substituida. Reivindicación 1: Un proceso para la preparación de oxi-(1H)-quinolin-2-onas 5-(a-haloacetilo)-8-sustituidas y caracterizado porque comprende: (a) hacer reaccionar (i) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación y un ácido Lewis para formar 5-acetil-8-hidroxi-(1H)quinolin-2-ona; o (ii) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación para formar 8-acetoxi-(1H)-quinolin-2-ona, y tratar, in-situ, la 8-acetoxi-(1H)-quinolin-2-ona con un ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; (b) hacer reaccionar la 5-acetil-8-hidroxi-(1H)-quinolin-2-ona preparada en la Etapa (a) con un compuesto que tiene la fórmula RL en la presencia de una base y un disolvente para formar 5-acetil-8-sustituido oxi-(1H)-quinolin-2-ona, en donde R es un grupo protector y L es un grupo saliente; y (c) hacer reaccionar la 5-acetil-8-sustituida oxi-(1H)-quinolin-2-ona con un agente de halogenación en presencia de un disolvente para formar una 5-(a-haloacetilo)-8-sustituido oxi-(1H)-quinolin-2-ona. Reivindicación 14: Un proceso para la preparación de sales de 5-[(R)-(5,6-2-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1H)-quinolinona-2-ona que comprende: (a) hacer reaccionar (i) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación y un ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; o (ii) 8-hidroxi-(1H)-quinolin-2-ona con un agente de acilación para formar 8-acetoxi-(1H)-quinolin-2-ona, y tratar, in-situ, la 8-acetoxi-(1H)quinolin-2-ona con un ácido Lewis para formar 5-acetil-8-hidroxi-(1H)-quinolin-2-ona; o (b) hacer reaccionar la 5-acetil-8-hidroxi-(1H)-quinolin-2-ona preparada en la Etapa (i) con un compuesto que tiene la fórmula RL en la presencia de una base y un disolvente para formar 5-acetil-8-sustituido oxi-(1H)-quinolin-2-ona, en donde R es un grupo protector y L es un grupo saliente; (c) hacer reaccionar la 5-acetil-8-sustituida oxi-(1H)-quinolin-2-ona con un agente de halogenación en presencia de un disolvente para formar un anillo de 5-(a-haloacetilo)-8-sustituido oxi-(1H)-quinolin-2-ona; (d) hacer reaccionar un 5-(a-haloacetilo)-8-sustituido oxi-(1H)-quinolin-2-ona con un agente reductor en presencia de un catalizador quiral para formar 8-(oxi sustituida)-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-ona; e) tratar la 8-(oxi sustituido)-5-((R)-2-halo-1-hidroxi-etil)-(1H)-quinolin-2-ona con una base en presencia de un disolvente para formar 8-(oxi sustituida)-5-(R)-oxiranil-(1H)-quinolin-2-ona; (f) hacer reaccionar la 8-oxi sustituido-5-(R)-oxiranil-(1H)-quinolin-2-ona que tiene la fórmula (1) con 2-amino-(5,6-dietil)-indano para formar una mezcla de reacción que contiene compuestos que tienen las fórmulas (2), (3) y (4) en la que R es un grupo protector; (g) tratar la mezcla de reacción preparada en el paso (f) con un ácido en presencia de un disolvente para formar una sal correspondiente; (h) aislar y cristalizar una sal que tiene la fórmula (5) en la que R es un grupo protector y A⁻ es un anión; (i) eliminar el grupo protector de la sal que tiene la fórmula (5) en presencia de un disolvente para formar una sal que tiene la fórmula (6) en la que A⁻ es un anión; (j) tratar la sal que tiene la fórmula (6) con un ácido en presencia de un disolvente para formar 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1H)-quinolin-2-ona que tiene la fórmula (7) en la que X⁻ es un anión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45972403P | 2003-04-02 | 2003-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103508A2 true AR103508A2 (es) | 2017-05-17 |
Family
ID=33131902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101105A AR043825A1 (es) | 2003-04-02 | 2004-04-01 | Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas |
| ARP160100188A AR103508A2 (es) | 2003-04-02 | 2016-01-25 | PROCESO PARA LA PREPARACIÓN DE OXI-(1H)-QUINOLIN-2-ONAS 5-(a-HALOACETILO)-8-SUSTITUIDAS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101105A AR043825A1 (es) | 2003-04-02 | 2004-04-01 | Procesos de preparacion de 5-(haloacetil)-8-(oxisustituidos)-(1h)-quinolin-2-onas |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7605267B2 (es) |
| EP (1) | EP1613599B8 (es) |
| JP (1) | JP4726778B2 (es) |
| KR (1) | KR101073740B1 (es) |
| CN (1) | CN1774423A (es) |
| AR (2) | AR043825A1 (es) |
| AT (1) | ATE491690T1 (es) |
| AU (1) | AU2004226212B2 (es) |
| BR (1) | BRPI0409154B1 (es) |
| CA (1) | CA2520990C (es) |
| CL (1) | CL2004000706A1 (es) |
| CO (1) | CO5700779A2 (es) |
| CY (1) | CY1111515T1 (es) |
| DE (1) | DE602004030553D1 (es) |
| DK (1) | DK1613599T3 (es) |
| EC (1) | ECSP056059A (es) |
| ES (1) | ES2358193T3 (es) |
| HK (1) | HK1086833A1 (es) |
| HR (1) | HRP20110184T1 (es) |
| IL (1) | IL171053A (es) |
| IS (1) | IS2800B (es) |
| MA (1) | MA27761A1 (es) |
| MX (1) | MXPA05010616A (es) |
| MY (1) | MY141871A (es) |
| NO (1) | NO331980B1 (es) |
| NZ (1) | NZ542623A (es) |
| PE (2) | PE20100399A1 (es) |
| PL (1) | PL1613599T3 (es) |
| PT (1) | PT1613599E (es) |
| RU (1) | RU2339621C2 (es) |
| SI (1) | SI1613599T1 (es) |
| TN (1) | TNSN05245A1 (es) |
| TW (1) | TWI324151B (es) |
| WO (1) | WO2004087668A1 (es) |
| ZA (1) | ZA200507603B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) * | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| CN101479245B (zh) | 2006-06-30 | 2013-05-22 | 诺瓦提斯公司 | 喹啉酮衍生物和其药物组合物 |
| WO2013132514A2 (en) * | 2012-03-09 | 2013-09-12 | Rao Davuluri Ramamohan | A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one |
| CN102633717B (zh) * | 2012-03-30 | 2013-11-20 | 西南大学 | N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用 |
| WO2014008640A1 (zh) * | 2012-07-11 | 2014-01-16 | 上海威智医药科技有限公司 | 茚达特罗中间体及茚达特罗的合成方法 |
| CZ306252B6 (cs) | 2013-03-15 | 2016-10-26 | Zentiva, K.S. | Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu) |
| EP3092217B1 (en) | 2014-01-09 | 2020-06-03 | Davuluri, Ramamohan Rao | A novel process for preparation of indacaterol or its pharmaceutically acceptable salts |
| CN105693603B (zh) * | 2014-11-24 | 2019-11-29 | 上海医药工业研究院 | 改良的马来酸茚达特罗制备工艺 |
| CN107531636B (zh) * | 2015-04-09 | 2022-11-25 | 正大天晴药业集团股份有限公司 | 茚达特罗或其盐的制备方法 |
| CN107868045A (zh) * | 2016-09-28 | 2018-04-03 | 四川海思科制药有限公司 | 一种茚达特罗中间体的制备方法 |
| CN108264483A (zh) * | 2016-12-31 | 2018-07-10 | 天津金耀集团有限公司 | 一种马来酸茚达特罗的制备方法 |
| CN109721534B (zh) * | 2018-09-25 | 2022-05-20 | 四川海思科制药有限公司 | 一种马来酸茚达特罗中间体及其制备方法和用途 |
| CN114751857A (zh) * | 2022-04-29 | 2022-07-15 | 梯尔希（南京）药物研发有限公司 | 一种茚达特罗杂质的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS539228B2 (es) * | 1974-01-31 | 1978-04-04 | ||
| CA1164459A (en) * | 1980-11-11 | 1984-03-27 | Yung-Hsiung Yang | Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives |
| JPS5896022A (ja) * | 1981-11-30 | 1983-06-07 | Otsuka Pharmaceut Co Ltd | 強心剤 |
| ES8403457A1 (es) * | 1983-01-28 | 1984-03-16 | Espanola Farma Therapeut | Procedimiento para la obtencion de un compuesto derivado de la 2-quinolinona. |
| ES8605239A1 (es) * | 1985-12-04 | 1986-03-16 | Astur Pharma | Un procedimiento para la preparacion de quinolonas sustitui-das |
| GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI324150B (en) * | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
-
2004
- 2004-03-31 PE PE2010000225A patent/PE20100399A1/es not_active Application Discontinuation
- 2004-03-31 PE PE2004000341A patent/PE20050211A1/es not_active Application Discontinuation
- 2004-03-31 TW TW093108942A patent/TWI324151B/zh not_active IP Right Cessation
- 2004-04-01 CN CNA2004800089560A patent/CN1774423A/zh active Pending
- 2004-04-01 NZ NZ542623A patent/NZ542623A/en not_active IP Right Cessation
- 2004-04-01 CA CA2520990A patent/CA2520990C/en not_active Expired - Lifetime
- 2004-04-01 AU AU2004226212A patent/AU2004226212B2/en not_active Expired
- 2004-04-01 CL CL200400706A patent/CL2004000706A1/es unknown
- 2004-04-01 AT AT04725035T patent/ATE491690T1/de active
- 2004-04-01 WO PCT/EP2004/003479 patent/WO2004087668A1/en active Application Filing
- 2004-04-01 BR BRPI0409154-0B1A patent/BRPI0409154B1/pt not_active IP Right Cessation
- 2004-04-01 JP JP2006504953A patent/JP4726778B2/ja not_active Expired - Lifetime
- 2004-04-01 MX MXPA05010616A patent/MXPA05010616A/es active IP Right Grant
- 2004-04-01 MY MYPI20041213A patent/MY141871A/en unknown
- 2004-04-01 SI SI200431618T patent/SI1613599T1/sl unknown
- 2004-04-01 DK DK04725035.2T patent/DK1613599T3/da active
- 2004-04-01 US US10/550,621 patent/US7605267B2/en active Active
- 2004-04-01 RU RU2005133664/04A patent/RU2339621C2/ru active
- 2004-04-01 AR ARP040101105A patent/AR043825A1/es not_active Application Discontinuation
- 2004-04-01 ES ES04725035T patent/ES2358193T3/es not_active Expired - Lifetime
- 2004-04-01 PL PL04725035T patent/PL1613599T3/pl unknown
- 2004-04-01 EP EP04725035A patent/EP1613599B8/en not_active Expired - Lifetime
- 2004-04-01 PT PT04725035T patent/PT1613599E/pt unknown
- 2004-04-01 DE DE602004030553T patent/DE602004030553D1/de not_active Expired - Lifetime
-
2005
- 2005-09-20 ZA ZA200507603A patent/ZA200507603B/en unknown
- 2005-09-22 IL IL171053A patent/IL171053A/en active IP Right Grant
- 2005-09-29 EC EC2005006059A patent/ECSP056059A/es unknown
- 2005-09-30 KR KR1020057018750A patent/KR101073740B1/ko active IP Right Grant
- 2005-09-30 TN TNP2005000245A patent/TNSN05245A1/en unknown
- 2005-10-11 MA MA28545A patent/MA27761A1/fr unknown
- 2005-10-12 CO CO05104250A patent/CO5700779A2/es active IP Right Grant
- 2005-10-27 IS IS8095A patent/IS2800B/is unknown
- 2005-11-01 NO NO20055099A patent/NO331980B1/no unknown
-
2006
- 2006-06-16 HK HK06106919.9A patent/HK1086833A1/xx not_active IP Right Cessation
-
2011
- 2011-03-14 CY CY20111100284T patent/CY1111515T1/el unknown
- 2011-03-14 HR HR20110184T patent/HRP20110184T1/hr unknown
-
2016
- 2016-01-25 AR ARP160100188A patent/AR103508A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103508A2 (es) | PROCESO PARA LA PREPARACIÓN DE OXI-(1H)-QUINOLIN-2-ONAS 5-(a-HALOACETILO)-8-SUSTITUIDAS | |
| AR043406A1 (es) | Procedimiento para preparar la sal de 5-[(r)-2-(5, 6- dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona | |
| CA2992211A1 (en) | Prodrugs of fumarates and their use in treating various diseases | |
| PE20060304A1 (es) | Procedimiento para preparar sales de oxi-5-[(r)-2-halo-1-hidroxi-etil]-(1h)-quinolin-2-onas 8 sustituidas | |
| PA8676301A1 (es) | Metodos para sintetizar derivados de 6-alquilaminoquinolina | |
| JP2018534912A5 (es) | ||
| PE20091364A1 (es) | Proceso para la preparacion de inhibidores de nep | |
| HK1121443A1 (en) | (1-aza-bicyclo | |
| RU2008153041A (ru) | Производные фторалкоксикомбретастатина, способы их производства и использования | |
| BR112019005294A2 (pt) | processo para preparar (±)-2-exo-(2-metilbenzilóxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano de fórmula (i) e método para prevenir ou reduzir a formação de depósitos no interior de um reator | |
| KR950011445A (ko) | 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도 | |
| US4074013A (en) | Corrodible iron-containing surfaces carrying corrosion-inhibiting coating | |
| ATE377593T1 (de) | 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung | |
| AR053722A2 (es) | Procedimiento para preparar secretagogos de hormonas del crecimiento y poliformo de los compuestos obtenidos | |
| BR0211291A (pt) | Derivados de diamina, processo para produção dos derivados de diamina e fungicidas contendo os derivados de diamina como ingrediente ativo | |
| PE20070526A1 (es) | Metodos para preparar derivados de acido glutamico | |
| JPS5466686A (en) | Quinoline-3-carboxylic acid derivative, its preparation, and pharmaceutical composition containig the same | |
| US4017628A (en) | Treatment of mange | |
| CA2894080A1 (en) | Non-alkyl pyridine sour corrosion inhibitors and methods for making and using same | |
| Teli et al. | Unveiling the cutting-edge synthetic methods and multifaceted applications of bis (pyrazolyl) methanes: A comprehensive review of recent advances | |
| KR850005291A (ko) | 에탈렌글리콜의 제법, 이에 사용되는 촉매조성물 및 동촉매 조성물의 제법 | |
| BR8206296A (pt) | Processo para a preparacao de um compostos;composicao reguladora de crescimento de plantas;processo para regular o crescimento de plantas | |
| PE20080312A1 (es) | Metodos para preparar derivados de acido glutamico e intermediarios del mismo | |
| BRPI0514412A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(gama) ppar(alfa) | |
| DE60028990D1 (de) | Verfahren zur herstellung von aliphatischen carboxylatenmit piperazinsubstituenten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |